Paper36988504
Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.
Al-Mansour F and 7 others. Aging (Albany NY), 2023. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic. Papers, record 36988504. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36988504
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Histone Deacetylase Inhibitors | Major topic |
| Phosphatidylinositol 3-Kinases | Major topic |
| Senotherapeutics | |
| Tumor Suppressor Protein p53 | |
| Phosphoinositide-3 Kinase Inhibitors | |
| Cellular Senescence | |
| Morpholines | |
| Pyrimidines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/W00190X/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
References89
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27049457 | Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27049457 | PubMed |
| 2 | 30826201 | Radiotherapy-Induced Senescence and its Effects on Responses to Treatment. | Clin Oncol (R Coll Radiol) | 2019 | https://conductscience.org/library/papers/30826201 | PubMed |
| 3 | 31285545 | A functional genetic screen defines the AKT-induced senescence signaling network. | Cell Death Differ | 2020 | https://conductscience.org/library/papers/31285545 | PubMed |
| 4 | 34916492 | Targeting PI3K/Akt signal transduction for cancer therapy. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34916492 | PubMed |
| 5 | 28507307 | A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC. | Sci Rep | 2017 | https://conductscience.org/library/papers/28507307 | PubMed |
| 6 | 16397526 | Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16397526 | PubMed |
| 7 | 10597302 | Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. | Oncogene | 1999 | https://conductscience.org/library/papers/10597302 | PubMed |
| 8 | 32235364 | Therapy-Induced Senescence: An "Old" Friend Becomes the Enemy. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32235364 | PubMed |
| 9 | 27341653 | Identification of Senescent Cells in the Bone Microenvironment. | J Bone Miner Res | 2016 | https://conductscience.org/library/papers/27341653 | PubMed |
| 10 | 35456986 | Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35456986 | PubMed |
| 11 | 28860342 | CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. | Haematologica | 2017 | https://conductscience.org/library/papers/28860342 | PubMed |
| 12 | 21321098 | Four faces of cellular senescence. | J Cell Biol | 2011 | https://conductscience.org/library/papers/21321098 | PubMed |
| 13 | 32161396 | The role of cellular senescence in ageing and endocrine disease. | Nat Rev Endocrinol | 2020 | https://conductscience.org/library/papers/32161396 | PubMed |
| 14 | 31675495 | Cellular Senescence: Defining a Path Forward. | Cell | 2019 | https://conductscience.org/library/papers/31675495 | PubMed |
| 15 | 31736210 | Amelioration of age-related brain function decline by Bruton's tyrosine kinase inhibition. | Aging Cell | 2020 | https://conductscience.org/library/papers/31736210 | PubMed |
| 16 | 14612402 | Influence of induced reactive oxygen species in p53-mediated cell fate decisions. | Mol Cell Biol | 2003 | https://conductscience.org/library/papers/14612402 | PubMed |
| 17 | 23521863 | Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. | Aging Cell | 2013 | https://conductscience.org/library/papers/23521863 | PubMed |
| 18 | 32233024 | Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. | Aging Cell | 2020 | https://conductscience.org/library/papers/32233024 | PubMed |
| 19 | 26915294 | Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma. | Cell Death Differ | 2016 | https://conductscience.org/library/papers/26915294 | PubMed |
| 20 | 23746838 | The hallmarks of aging. | Cell | 2013 | https://conductscience.org/library/papers/23746838 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42439909 | Cellular senescence and aging: molecular mechanisms and convergent pathways. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/42439909 | PubMed |
| 42178984 | Senolytic Therapy as a Preventive Strategy for Spine Degeneration and Pain. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42178984 | PubMed |
| 41972901 | Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy. | Epilepsia | 2026 | https://conductscience.org/library/papers/41972901 | PubMed |
| 41850873 | Epigenetic dynamics of cellular senescence: From mechanistic insights to precision senotherapy. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/41850873 | PubMed |
| 41424791 | The PI3K/AKT/mTOR pathway in scar remodeling and keloid formation: mechanisms and therapeutic perspectives. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41424791 | PubMed |
| 41204284 | The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41204284 | PubMed |
| 40886198 | Interrogating the regulatory epigenome of cellular senescence. | Cell Mol Life Sci | 2025 | https://conductscience.org/library/papers/40886198 | PubMed |
| 40572616 | Development and Application of a Senolytic Predictor for Discovery of Novel Senolytic Compounds and Herbs. | Molecules | 2025 | https://conductscience.org/library/papers/40572616 | PubMed |
| 40155379 | Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction. | Nat Commun | 2025 | https://conductscience.org/library/papers/40155379 | PubMed |
| 40085710 | Senolytic treatment for low back pain. | Sci Adv | 2025 | https://conductscience.org/library/papers/40085710 | PubMed |
| 39858413 | The Intersection of Epigenetics and Senolytics in Mechanisms of Aging and Therapeutic Approaches. | Biomolecules | 2024 | https://conductscience.org/library/papers/39858413 | PubMed |
| 39693021 | Unlocking the Potential of Senolytic Compounds: Advancements, Opportunities, and Challenges in Ageing-Related Research. | Subcell Biochem | 2024 | https://conductscience.org/library/papers/39693021 | PubMed |
| 39575133 | Reversing Aging and Improving Health Span in Glaucoma Patients: The Next Frontier? | J Curr Glaucoma Pract | 2024 | https://conductscience.org/library/papers/39575133 | PubMed |
| 38739931 | Revolutionizing Diabetic Foot Ulcer Care: The Senotherapeutic Approach. | Aging Dis | 2024 | https://conductscience.org/library/papers/38739931 | PubMed |
| 38458774 | A Conversation with ChatGPT on Contentious Issues in Senescence and Cancer Research. | Mol Pharmacol | 2024 | https://conductscience.org/library/papers/38458774 | PubMed |
| 37509121 | Counteracting Immunosenescence-Which Therapeutic Strategies Are Promising? | Biomolecules | 2023 | https://conductscience.org/library/papers/37509121 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36988504
GET https://conductscience.org/api/papers/v1/36988504/references?page=2